Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC. Reichardt P, et al. Among authors: soulieres d. BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5. BMC Cancer. 2016. PMID: 26772734 Free PMC article. Clinical Trial.
Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.
Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Blackstein ME, et al. Among authors: soulieres d. Can J Gastroenterol. 2006 Mar;20(3):157-63. doi: 10.1155/2006/434761. Can J Gastroenterol. 2006. PMID: 16550259 Free PMC article.
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225. Heinrich MC, et al. Among authors: soulieres d. Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575. Clin Cancer Res. 2008. PMID: 18451237 Clinical Trial.
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Soulières D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D. Soulières D, et al. BMC Cancer. 2016 Jan 14;16:19. doi: 10.1186/s12885-016-2064-0. BMC Cancer. 2016. PMID: 26768732 Free PMC article. Clinical Trial.
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulières D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P. Bahig H, et al. Among authors: soulieres d. BMC Cancer. 2019 Jan 14;19(1):68. doi: 10.1186/s12885-019-5266-4. BMC Cancer. 2019. PMID: 30642290 Free PMC article. Clinical Trial.
Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
Clavel S, Nguyen DH, Fortin B, Després P, Khaouam N, Donath D, Soulières D, Guertin L, Nguyen-Tan PF. Clavel S, et al. Among authors: soulieres d. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):582-9. doi: 10.1016/j.ijrobp.2010.10.061. Epub 2011 Feb 1. Int J Radiat Oncol Biol Phys. 2012. PMID: 21277695
199 results